Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality -16% Improvement Relative Risk ICU admission -16% c19early.org/e Zekri-Nechar et al. Aspirin for COVID-19 LATE Favors aspirin Favors control
Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients
Zekri-Nechar et al., Medicina, doi:10.3390/medicina58111649
15 Nov 2022    Source   PDF   Share   Tweet
Retrospective 201 consecutive elderly hospitalized patients in Spain, showing higher mortality with aspirin use in unadjusted results. The aspirin group was older and had higher prevalence of hypertension and dyslipidemia. Table 1 shows the same counts for mortality and ICU, but different p values.
risk of death, 16.2% higher, RR 1.16, p = 0.57, treatment 14 of 41 (34.1%), control 47 of 160 (29.4%).
risk of ICU admission, 16.2% higher, RR 1.16, p = 0.57, treatment 14 of 41 (34.1%), control 47 of 160 (29.4%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in meta analysis: unadjusted differences between groups; inconsistent data.
Zekri-Nechar et al., 15 Nov 2022, retrospective, Spain, peer-reviewed, 10 authors.
Contact: jjzamorano@ucm.es (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit